Ricardo Fernandes1, Sasha Mazzarello2, Brian Hutton3, Risa Shorr4, Habeeb Majeed5, Mohammed Fk Ibrahim1, Carmel Jacobs1, Michael Ong1, Mark Clemons6,7. 1. Department of Medicine, Division of Medical Oncology, The Ottawa Hospital Cancer Centre and University of Ottawa, 501 Smyth Road, Ottawa, Canada. 2. Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada. 3. Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada. 4. The Ottawa Hospital, Ottawa, Canada. 5. Department of Medicine, Division of Internal Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Canada. 6. Department of Medicine, Division of Medical Oncology, The Ottawa Hospital Cancer Centre and University of Ottawa, 501 Smyth Road, Ottawa, Canada. mclemons@toh.on.ca. 7. Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Canada. mclemons@toh.on.ca.
Abstract
BACKGROUND: Taxane acute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 24-48 h after taxane-based chemotherapy and lasting for 5-7 days. Relatively little is known about its incidence and impact on quality of life. OBJECTIVES: A systematic review was conducted evaluating the incidence of TAPS in breast cancer patients receiving taxane-based chemotherapy. METHODS: Embase, Cochrane, and Ovid MEDLINE were searched from 1947 to July 2015. Data was sought from randomized controlled trials (RCTs), prospective and retrospective observational studies. Two reviewers independently screened citations and full text articles. Outcomes of interest were the incidence of TAPS and its impact on quality of life. RESULTS: Of 980 citations identified, 51 relevant studies (27,007 patients) were included. Data came from RCTs (12,357 patients), retrospective (6566 patients) and prospective observational studies (6210 patients). Study sample sizes ranged from 14 to 4149 patients (median 152). Given the significance between study heterogeneity, a meta-analysis was not performed. The incidence of TAPS varied between taxanes: paclitaxel (median 13.1 %, range 0.9-86 %), docetaxel (median 10.5 %, range 3.6-70 %), and nab-paclitaxel (26 %, range 14-43 %). In the metastatic setting, median incidence was 30 % (range 5.4-73 %), compared with 11.3 % (range 0.9-86 %) in the adjuvant setting. Three out of eight studies assessing quality of life demonstrated pain interference with daily activities. CONCLUSIONS: The incidence of TAPS varies between taxanes, regimens, and disease settings. In order to identify patients at the greatest risk of TAPS, and hence optimize its prevention and management, standardized methods of diagnosing and measuring TAPS are needed.
BACKGROUND:Taxaneacute pain syndrome (TAPS) is characterized by myalgias and arthralgias starting 24-48 h after taxane-based chemotherapy and lasting for 5-7 days. Relatively little is known about its incidence and impact on quality of life. OBJECTIVES: A systematic review was conducted evaluating the incidence of TAPS in breast cancerpatients receiving taxane-based chemotherapy. METHODS: Embase, Cochrane, and Ovid MEDLINE were searched from 1947 to July 2015. Data was sought from randomized controlled trials (RCTs), prospective and retrospective observational studies. Two reviewers independently screened citations and full text articles. Outcomes of interest were the incidence of TAPS and its impact on quality of life. RESULTS: Of 980 citations identified, 51 relevant studies (27,007 patients) were included. Data came from RCTs (12,357 patients), retrospective (6566 patients) and prospective observational studies (6210 patients). Study sample sizes ranged from 14 to 4149 patients (median 152). Given the significance between study heterogeneity, a meta-analysis was not performed. The incidence of TAPS varied between taxanes: paclitaxel (median 13.1 %, range 0.9-86 %), docetaxel (median 10.5 %, range 3.6-70 %), and nab-paclitaxel (26 %, range 14-43 %). In the metastatic setting, median incidence was 30 % (range 5.4-73 %), compared with 11.3 % (range 0.9-86 %) in the adjuvant setting. Three out of eight studies assessing quality of life demonstrated pain interference with daily activities. CONCLUSIONS: The incidence of TAPS varies between taxanes, regimens, and disease settings. In order to identify patients at the greatest risk of TAPS, and hence optimize its prevention and management, standardized methods of diagnosing and measuring TAPS are needed.
Entities:
Keywords:
Breast cancer; Incidence; Pain; Quality of life; Taxane chemotherapy
Authors: Carol M Moinpour; Gary W Donaldson; Astra M Liepa; Allen S Melemed; Joyce O'Shaughnessy; Kathy S Albain Journal: Qual Life Res Date: 2011-09-16 Impact factor: 4.147
Authors: Charles L Loprinzi; Brandi N Reeves; Shaker R Dakhil; Jeff A Sloan; Sherry L Wolf; Kelli N Burger; Arif Kamal; Nguyet A Le-Lindqwister; Gamini S Soori; Anthony J Jaslowski; Paul J Novotny; Daniel H Lachance Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Roy E Smith; Stewart J Anderson; Ann Brown; Aaron P Scholnik; Ajit M Desai; Carl G Kardinal; Barry C Lembersky; Eleftherios P Mamounas Journal: Clin Breast Cancer Date: 2002-12 Impact factor: 3.225
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: Eva J Kantelhardt; Martina Vetter; Marcus Schmidt; Corinne Veyret; Doris Augustin; Volker Hanf; Christoph Meisner; Daniela Paepke; Manfred Schmitt; Fred Sweep; Gunter von Minckwitz; Pierre-Marie Martin; Fritz Jaenicke; Christoph Thomssen; Nadia Harbeck Journal: BMC Cancer Date: 2011-04-16 Impact factor: 4.430
Authors: Nicholas Chiu; Liying Zhang; Rebecca Dent; Angie Giotis; Jenna van Draanen; Daniela Gallo-Hershberg; Leonard Chiu; Ronald Chow; Bo Angela Wan; Mark Pasetka; Jordan Stinson; Erica Stacey; Sunil Verma; Henry Lam; Edward Chow; Carlo DeAngelis Journal: Support Care Cancer Date: 2017-07-22 Impact factor: 3.603
Authors: Mark Clemons; Demetrios Simos; Marta Sienkiewicz; Terry Ng; Labib Zibdawi; Bassam Basulaiman; Arif Awan; Dean Fergusson; Lisa Vandermeer; Deanna Saunders; Brian Hutton; Eitan Amir Journal: Support Care Cancer Date: 2021-03-19 Impact factor: 3.603
Authors: David Hao; Shawn Sidharthan; Juan Cotte; Mary Decker; Mariam Salisu-Orhurhu; Dare Olatoye; Jay Karri; Jonathan M Hagedorn; Peju Adekoya; Charles Odonkor; Amitabh Gulati; Vwaire Orhurhu Journal: Curr Pain Headache Rep Date: 2021-05-07
Authors: R Fernandes; S Mazzarello; A A Joy; G R Pond; J Hilton; M F K Ibrahim; C Canil; M Ong; C Stober; L Vandermeer; B Hutton; M da Costa; S Damaraju; Mark Clemons Journal: Support Care Cancer Date: 2018-03-21 Impact factor: 3.603
Authors: Rashi Asthana; Liying Zhang; Bo Angela Wan; Daniela Gallo-Hershberg; Angie Giotis; Mark Pasetka; Jenna van Draanen; Shannon Goodall; Patrick L Diaz; Leah Drost; Edward Chow; Carlo De Angelis Journal: Support Care Cancer Date: 2019-05-17 Impact factor: 3.603
Authors: John Hilton; Carol Stober; Sasha Mazzarello; Lisa Vandermeer; Dean Fergusson; Brian Hutton; Mark Clemons Journal: PLoS One Date: 2018-07-24 Impact factor: 3.240